Al-Omari Awad, Rabaan Ali A, Salih Samer, Al-Tawfiq Jaffar A, Memish Ziad A
Critical Care and Infection Control Department, Dr. Sulaiman Al-Habib Medical Group, and Al-Faisal University, Riyadh, Saudi Arabia.
Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
Diagn Microbiol Infect Dis. 2019 Mar;93(3):265-285. doi: 10.1016/j.diagmicrobio.2018.10.011. Epub 2018 Oct 18.
In September 2012, a novel coronavirus was isolated from a patient who died in Saudi Arabia after presenting with acute respiratory distress and acute kidney injury. Analysis revealed the disease to be due to a novel virus which was named Middle East Respiratory Coronavirus (MERS-CoV). There have been several MERS-CoV hospital outbreaks in KSA, continuing to the present day, and the disease has a mortality rate in excess of 35%. Since 2012, the World Health Organization has been informed of 2220 laboratory-confirmed cases resulting in at least 790 deaths. Cases have since arisen in 27 countries, including an outbreak in the Republic of Korea in 2015 in which 36 people died, but more than 80% of cases have occurred in Saudi Arabia.. Human-to-human transmission of MERS-CoV, particularly in healthcare settings, initially caused a 'media panic', however human-to-human transmission appears to require close contact and thus far the virus has not achieved epidemic potential. Zoonotic transmission is of significant importance and evidence is growing implicating the dromedary camel as the major animal host in spread of disease to humans. MERS-CoV is now included on the WHO list of priority blueprint diseases for which there which is an urgent need for accelerated research and development as they have the potential to cause a public health emergency while there is an absence of efficacious drugs and/or vaccines. In this review we highlight epidemiological, clinical, and infection control aspects of MERS-CoV as informed by the Saudi experience. Attention is given to recommended treatments and progress towards vaccine development.
2012年9月,从一名在沙特阿拉伯出现急性呼吸窘迫和急性肾损伤后死亡的患者身上分离出一种新型冠状病毒。分析显示,该疾病是由一种新型病毒引起的,这种病毒被命名为中东呼吸综合征冠状病毒(MERS-CoV)。沙特阿拉伯发生了几起MERS-CoV医院内疫情,一直持续到现在,该疾病的死亡率超过35%。自2012年以来,世界卫生组织已收到2220例实验室确诊病例的通报,至少造成790人死亡。此后,27个国家出现了病例,包括2015年韩国爆发的疫情,其中36人死亡,但超过80%的病例发生在沙特阿拉伯。MERS-CoV的人际传播,尤其是在医疗环境中,最初引起了“媒体恐慌”,然而人际传播似乎需要密切接触,到目前为止,该病毒尚未具备流行潜力。人畜共患传播非常重要,越来越多的证据表明单峰骆驼是该疾病传播给人类的主要动物宿主。MERS-CoV现已被列入世界卫生组织的优先蓝图疾病清单,由于这些疾病有可能引发公共卫生紧急事件,而目前又缺乏有效的药物和/或疫苗,因此迫切需要加快研究和开发。在本综述中,我们重点介绍了沙特经验所揭示MERS-CoV的流行病学、临床和感染控制方面。还关注了推荐的治疗方法和疫苗研发进展。